Interaction Checker

Interacciones de Octreotida

Octreotida (Sandostatin, Bynfezia, Mycapssa) tiene 125 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 125; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (125)

  • AcarbosaantidiabéticoModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • AcebutololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Alogliptinainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • AtenololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Bexagliflozinainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Bicarbonato de sodioantiácidoModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • BisoprololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Bromocriptinaagonista de la dopaminaModerada

    Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Canagliflozinainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Dapagliflozinainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Dapagliflozina y metforminainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Dexlansoprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Digoxinaglucósido digitálicoModerada

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Dorzolamida y timololinhibidor de la anhidrasa carbónicaModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Dulaglutidaagonista del receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Empagliflozinainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Empagliflozina y metforminainhibidor de SGLT2Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • EsmololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Esomeprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • EstradiolestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Estrógenos conjugados y bazedoxifenoestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Estrógenos esterificados y metiltestosteronaestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Etonogestrel y etinilestradiolestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Exenatidaagonista del receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Famotidinaantagonista H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • FulvestrantestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • GlibenclamidasulfonilureaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Glibenclamida y metforminasulfonilureaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • GlimepiridasulfonilureaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • GlipizidasulfonilureaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Glipizida y metforminasulfonilureaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • GlucagónModerada

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (etiqueta de Octreotida, Advertencias y precauciones)

  • Ibuprofeno y famotidinaAINEModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Insulina aspartainsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Insulina degludecinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Insulina detemirinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Insulina glarginainsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Insulina lisproinsulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Insulina regular (humana)insulinaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • LabetalolbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Lansoprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • LevonorgestrelprogestágenoModerada

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (etiqueta de Octreotida, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (etiqueta de Octreotida, Interacciones medicamentosas)

  • Levotiroxinahormona tiroideaModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • Linagliptinainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Linagliptina y metforminainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Liotironinahormona tiroideaModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • Liraglutidaagonista del receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAModerada

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • MedroxiprogesteronaprogestágenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • MegestrolprogestágenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • MetforminabiguanidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Mifepristonainhibidor de CYP3A4Moderada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • MiglitolantidiabéticoModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • NadololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Naproxeno y esomeprazolAINEModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • NateglinidameglitinidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • NebivololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Nizatidinaantagonista H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Norelgestromina y etinilestradiolestrógenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • NoretisteronaprogestágenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Omeprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Pantoprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • PindololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • PioglitazonatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Pioglitazona y metforminatiazolidinedionaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • ProgesteronaprogestágenoModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • Propiltiouracilofármaco antitiroideoModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • QuinidinaantiarrítmicoModerada

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Rabeprazolinhibidor de la bomba de protonesModerada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Ranitidinaantagonista H2Moderada

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • RepaglinidameglitinidaModerada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Saxagliptinainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Saxagliptina y metforminainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Semaglutidaagonista del receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Sitagliptinainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Sitagliptina y metforminainhibidor de la DPP-4Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • SotalolbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • TelotristatModerada

    Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (etiqueta de Telotristat, Interacciones medicamentosas)

  • Teriparatidahormona tiroideaModerada

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

  • TimololbetabloqueanteModerada

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (etiqueta de Octreotida, Advertencias y precauciones)

  • Tirzepatidaagonista del receptor de GLP-1Moderada

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioModerada

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • Vitamina B12Vitaminas y mineralesModerada

    Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (etiqueta de Octreotida, Advertencias y precauciones)

Compruebe Octreotida frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.